Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.92)
# 3,081
Out of 4,944 analysts
97
Total ratings
37.04%
Success rate
-8.95%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.47 | +102.43% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $1.86 | +168.82% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.23 | +169.06% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $18.85 | +138.73% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $63.76 | +31.74% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $120.02 | -8.35% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $37.95 | +0.13% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $13.72 | +9.33% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $64.04 | -17.24% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.43 | +311.52% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $35.26 | +98.53% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.92 | +4.44% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.65 | +1,051.52% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $6.41 | +196.41% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.54 | +490.55% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $36.33 | -0.91% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.14 | +551.47% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.48 | +20.24% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $10.02 | +249.30% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.68 | +561.76% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.25 | +2,300.00% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.12 | +1,685.71% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $3.85 | +159.74% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.76 | +166.27% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.56 | +1,502.56% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.47 | -49.61% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $20.34 | -1.67% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.27 | -33.92% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $7.56 | +2,546.34% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.63 | +427.90% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.28 | +4,587.50% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $3.00 | +500.00% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.47
Upside: +102.43%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $1.86
Upside: +168.82%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.23
Upside: +169.06%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $18.85
Upside: +138.73%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $63.76
Upside: +31.74%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $120.02
Upside: -8.35%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $37.95
Upside: +0.13%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $13.72
Upside: +9.33%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $64.04
Upside: -17.24%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.43
Upside: +311.52%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $35.26
Upside: +98.53%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.92
Upside: +4.44%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.65
Upside: +1,051.52%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $6.41
Upside: +196.41%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.54
Upside: +490.55%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $36.33
Upside: -0.91%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.14
Upside: +551.47%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.48
Upside: +20.24%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $10.02
Upside: +249.30%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.68
Upside: +561.76%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.25
Upside: +2,300.00%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.12
Upside: +1,685.71%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $3.85
Upside: +159.74%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $6.76
Upside: +166.27%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.56
Upside: +1,502.56%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.47
Upside: -49.61%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $20.34
Upside: -1.67%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.27
Upside: -33.92%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $7.56
Upside: +2,546.34%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $6.63
Upside: +427.90%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.28
Upside: +4,587.50%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $3.00
Upside: +500.00%